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Purpose: This article reviews the mechanism of action of trastuzumab emtansine (T-DM1), 
existing clinical data relating to its use for human growth factor receptor 2 (HER2)-positive breast 
cancer, potential pathways of resistance, and ongoing studies evaluating this novel agent.
Background: The development of HER2-targeted therapies has dramatically improved clinical 
outcomes for patients with any stage of HER2-positive breast cancer. Although the positive effect 
of these treatments cannot be overstated, treatment resistance develops in the vast majority of 
those diagnosed with stage IV HER2-positive breast cancer. Moreover, HER2-directed therapies 
are most effective when combined with cytotoxic chemotherapy. The need for chemotherapy 
leads to significant adverse effects and a clear decrease in quality of life for those dealing with 
a chronic incurable disease. T-DM1 is a recently developed, novel antibody–drug conjugate in 
which highly potent maytanisinoid chemotherapy is stably linked to the HER2-targeted mono-
clonal antibody, trastuzumab.
Results: Preclinical and phase 1–3 clinical data support the significant antitumor activity of 
T-DM1. Importantly, several randomized studies also now demonstrate its clear superiority 
in terms of tolerability compared with standard chemotherapy-containing regimens. Its role 
in the treatment of trastuzumab-resistant metastatic breast cancer has now been established on 
the basis of the results of two phase 3 randomized studies, EMILIA (An Open-label Study of 
Trastuzumab Emtansine (T-DM1) vs Capecitabine + Lapatinib in Patients With HER2-positive 
Locally Advanced or Metastatic Breast Cancer) and TH3RESA (A Study of Trastuzumab 
Emtansine in Comparison With Treatment of Physician’s Choice in Patients With HER2-positive 
Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy). 
The most common toxicities seen with T-DM1 are thrombocytopenia and an elevation in liver 
transaminases. Significant cardiac toxicity has not been demonstrated. Both in vitro cell line–
based studies as well as exploratory analyses of archived tumor samples from the clinical trials 
are seeking to understand potential mechanisms of resistance to T-DM1. Ongoing studies are 
also evaluating the use of T-DM1 in the first-line metastatic, neoadjuvant, and adjuvant settings, 
as well as in combination with other targeted therapies.
Conclusion: T-DM1 represents the first successfully developed antibody drug conjugate for 
the treatment of HER2-positive advanced breast cancer.
Keywords: HER2, T-DM1, trastuzumab emtansine, ado-trastuzumab emtansine, metastatic 
breast cancer, Kadcyla
Introduction
Nearly three decades have passed since Slamon and colleagues demonstrated that 
amplification of the gene for human epidermal human growth factor receptor 2 
(HER2) is associated with a more aggressive disease course and worse clinical 
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outcomes in patients with breast cancer.1 Trastuzumab 
(Herceptin; Genentech, South San Francisco, CA, USA), 
the first monoclonal antibody developed to target HER2, 
was shown to significantly improve the time to progression 
and overall survival (OS) of patients with metastatic HER2+ 
breast cancer.2 Significant disease-free survival and OS 
benefits were subsequently demonstrated in patients with 
localized HER2-positive (HER2+) disease with the addi-
tion of trastuzumab to standard adjuvant chemotherapy.3–5 
In fact, trastuzumab has literally altered the natural history 
of HER2 overexpressing disease in both the metastatic and 
early disease settings, such that the survival for patients 
with trastuzumab-treated HER2+ breast cancer now mir-
rors, and may exceed, that of HER2-negative breast cancer.6,7 
Despite the substantial activity of trastuzumab, resistance 
to therapy arises in the majority of patients with advanced 
disease. Lapatinib (Tykerb; GlaxoSmithKline, Brentford, 
United Kingdom), an orally bioavailable reversible inhibi-
tor of the HER1 and HER2 tyrosine kinase domains, was 
subsequently shown to improve the time to progression for 
patients with HER2+ trastuzumab-pretreated metastatic 
breast cancer (MBC),8 leading to the US Food and Drug 
Administration (FDA) approving lapatinib plus capecitabine 
in this disease setting. Although this therapy provides patients 
with trastuzumab-resistant disease an additional treatment 
option, only 29% of patients had clinical benefit (complete 
response, partial response, or stable disease lasting at least 
6 months), and half of patients had disease progression at 
6.2 months.9 A variety of resistance mechanisms has been 
proposed including activation of alternative signaling path-
ways, receptor masking, truncated HER2, or expression of 
the ligands of other members of the epidermal growth factor 
receptor family.10 Therefore, there is a continued need to 
develop novel agents to target HER2-amplified disease. In 
2013, the FDA approved the first successful HER2-targeted 
antibody–drug conjugate (ADC), trastuzumab emtansine 
(T-DM1; Kadcyla; Genentech), for the treatment of HER2+ 
trastuzumab-pretreated advanced breast cancer. This article 
reviews the mechanism of action of T-DM1, as well as exist-
ing clinical data, ongoing studies, and potential pathways of 
resistance to this novel agent.
Mechanism of action of T-DM1
T-DM1 is a novel ADC composed of trastuzumab connected 
via a stable thioether linker to a highly potent antimicro-
tubule derivative of maytansine 1 (DM1; N-methyl-N-[3-
mercapto-1-oxopropyl]-l-alanine ester of maytansinol). 
DM1 is an inhibitor of microtubule dimerization, similar 
to vinka alkaloids, chosen as the cytotoxic component of 
T-DM1, given its high potency. In vitro studies have shown 
that in cancer cell lines, DM1 is 25–270 times more potent 
than paclitaxel.11 On average, 3.5 moieties of DM1 are linked 
via a nonreducible thioether bond (4-[N-maleimidomethyl] 
cyclohexane-1-carboxylate) to each trastuzumab antibody.12 
T-DM1 is not the first ADC developed clinically; however, it is 
unique in that it is the first to use the 4-(N- maleimidomethyl) 
cyclohexane-1-carboxylate linker. Prior ADCs were designed 
using disulfide bond linkers, but experimental work showed 
that the oxidizing potential of lysosomes limited the cleavage 
of the disulfide bond within the cell.13 The 4-(N-maleimidom-
ethyl) cyclohexane-1-carboxylate linker is advantageous, as 
it undergoes proteolytic digestion once internalized, and fur-
thermore, given its greater stability, it is safer, as it limits the 
release of DM1 into the circulation.14 On binding the extracel-
lular domain of HER2, T-DM1 enters the cell by the process 
of receptor-mediated endocytosis, and DM1 dissociates from 
the linker by proteolysis, presumably in the lysosome.15 In the 
cell cytoplasm, DM1 disrupts microtubule dynamics leading 
to cell cycle arrest and induction of apoptosis.14 In addition 
to being a cytotoxic agent, T-DM1 maintains the activity of 
trastuzumab by inhibiting HER2-directed signal transduc-
tion as well as activating antibody-dependent cell-mediated 
cytotoxicity (Figure 1).11 Preclinical work by Lewis Phillips 
and colleagues in a mouse xenograft model demonstrated 
that although T-DM1 had minimal cytotoxic effects in breast 
cancer cell lines lacking HER2 overexpression, it was capable 
of eliciting cell death in HER2 overexpressing cell lines, 
including those resistant to trastuzumab.12 Pharmacokinetic 
evaluation across multiple studies shows that the half-life 
of T-DM1 is approximately 4 days, and the clearance of the 
drug is predominantly via the biliary and gastrointestinal 
systems.16
The HER2-targeted nature of T-DM1 should theoretically 
limit the delivery of the cytotoxic component to HER2+ 
cells. Despite this, thrombocytopenia has been observed 
in all clinical trials of T-DM1 to date. Mahapatra and col-
leagues studied the effects of T-DM1 on platelet formation 
from hematopoietic stem cells as well as platelet function 
in vitro and demonstrated that T-DM1 is internalized in a 
HER2-independent fashion into megakaryocytes and that the 
intracellular release of DM1 leads to a reduction in the stem 
cell population.17 More recently, Thon and coworkers evalu-
ated the rate and extent of megakaryocyte differentiation and 
proplatelet production in vitro, using a novel high-content, 
live cell imaging assay. Their work confirmed that T-DM1 is 
endocytosed into megakaryocytes and that DM1 disrupts the 
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microtubule cytoskeleton and inhibits proplatelet production 
while also inhibiting megakaryocyte differentiation.18
Completed clinical studies
Phase 1 trials
T-DM1 was first evaluated in a phase 1, open-label, mul-
ticenter, dose-escalation study (TDM3569g) in which 
patients with HER2+ MBC whose disease had progressed 
on prior trastuzumab-containing therapy were assigned to 
one of two dosing regimens: every 21 days or weekly.19,20 
The three (q3) weekly dosing cohort was enrolled first. A 
total of 24 patients received escalating doses of intravenous 
T-DM1 starting at 0.3 mg/kg every 21 days.19 The median 
number of prior regimens received in the metastatic setting 
was four (range, one to eight), and 58% of patients had at 
least three distinct sites of metastatic disease. Dose-limiting 
grade 4 thrombocytopenia was observed in two of three 
patients treated with 4.8 mg/kg, and the maximum tolerated 
dose (MTD) was identified as 3.6 mg/kg. In this heavily 
pretreated patient population, six of 24 patients achieved a 
partial response, five of which were confirmed, yielding an 
overall objective response rate (ORR) of 21%. A total of 15 
patients were treated with 3.6 mg/kg. The clinical benefit rate 
(objective response plus stable disease at 6 months) among 
the 15 patients who were treated at the MTD was 73%. Of 
these 15 patients, nine had measurable disease, including four 
patients who had a confirmed partial response for an ORR of 
44% (four of nine) in this group. The most commonly reported 
all-grade adverse events (AEs) were thrombocytopenia 
(54.2%), elevated transaminases (41.7%), fatigue (37.5%), 
anemia (29.2%), and nausea (25%). Of note, no neuropathy 
was noted in the study.19
In the second part of this study, 28 patients with HER2+ 
MBC were treated with escalating doses of weekly T-DM1, 
starting at 1.2 mg/kg.20 Two of three patients treated with 
2.9 mg/kg developed grade 3 AEs (one grade 3 aspartate ami-
Figure 1 Structure of trastuzumab emtansine and mechanisms of action.
Notes: On binding of trastuzumab emtansine (T-DM1) to human growth factor receptor 2 (HER2), T-DM1 is internalized and undergoes lysosomal degradation. This results in 
the release of DM1, which binds to tubulin, resulting in the suppression of microtubule dynamic instability and prevention of microtubule polymerization. T-DM1 has also been 
shown to retain mechanisms of action of trastuzumab, including disruption of HER2 signal transduction and antibody-dependent cellular cytotoxicity (ADCC). Reprinted by 
permission from the American Association for Cancer Research: LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. Trastuzumab emtansine: a unique antibody-drug 
conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res. 2011; 17(20):6437–6447. DOI: 10.1158/1078-0432.CCR-11-0762.41
Abbreviation: MCC, 4-[N-maleimidomethyl] cyclohexane-1-carboxylate.
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notransferase elevation and one grade 3 thrombocytopenia), 
thus establishing the MTD of the weekly regimen as 
2.4 mg/kg. Objective partial responses were seen in 13 of 
the 28 patients (46.4%). A total of 16 patients were treated 
at the MTD, 15 of whom had measurable disease. The ORR 
in these 15 patients was 40% (six of 15). Similar to the q3 
weekly dosing regimen,19 there was no grade 3 neuropathy 
observed, and the rate of grade 3/4 AEs (68%) was similar 
to that reported with the q3 weekly regimen (50%).20 It is 
interesting to consider that the weekly regimen delivers 
twice as much T-DM1 and, based on these data, appears to 
have similar tolerability to the q3 weekly regimen. Although 
the ORR of all patients enrolled is higher with the weekly 
regimen, given the very small size of this study, a relative 
comparison of efficacy is not possible. Ongoing studies are 
evaluating the weekly regimen further.21 A summary of Phase 
I trials are provided in Table 1.
Phase 2 trials
TDM4258 was a proof-of-concept phase 2 study to evalu-
ate the activity and safety of q3 weekly T-DM1 in patients 
with previously treated HER2+ MBC.22 In this single-group, 
open-label study, 112 heavily pretreated patients were 
enrolled. The median number of previous lines of therapy 
was 8 and included prior taxane (84%), anthracycline (71%), 
capecitabine (66%), and carboplatin (42%). Prior lapatinib 
was used in 60% of patients. The ORR was 25.9%, and the 
median progression-free survival (PFS) was 5.3 months by 
independent review. Among patients previously treated with 
lapatinib (n=66), the ORR was 24.2%, and the median PFS 
was 4.2 months. The safety profile was similar to that reported 
in the phase 1 studies. Importantly, no patients developed 
grade 3/4 congestive heart failure or left ventricular ejection 
fraction decline, and no patients came off study because of 
cardiac toxicity. HER2 status was evaluated centrally on 
tumors from 95 patients and was found to be positive in 74. 
The ORR in those patients with confirmed HER2+ tumors 
was 33.8%, and median PFS was 8.2 months. Interestingly, 
21 patients had HER2 normal tumors, and of those, only one 
patient had an objective response.22
A confirmatory, single-group phase 2 study (TDM4374g) 
of q3 weekly T-DM1 was conducted in 110 patients who 
had been previously exposed to trastuzumab, anthracyclines, 
taxanes, and capecitabine.23 In contrast to the TDM4258 
study,22 this study required patients to have received prior 
lapatinib. The primary endpoint was independently assessed 
ORR. The ORR was 34.5% (38/110), clinical benefit rate was 
48.2%, and duration of response was 7.2 months. The median 
PFS was 6.9 months by independent review. The ORR was 
similar for patients who had documented progression on 
prior lapatinib, trastuzumab, and chemotherapy. Central con-
firmation of HER2 status was performed on archival tumor 
tissue from 95 patients. Of these patients, 15 were found to 
be HER2 normal, three of whom had an objective response 
(20%). In contrast, 41% of patients with centrally confirmed 
HER2+ disease had an objective response. The most common 
all-grade AEs were fatigue, nausea, and thrombocytopenia, 
and the most frequent grade 3/4 AEs were thrombocytopenia, 
fatigue, and cellulitis. Elevation of aspartate aminotransferase 
occurred in 26%, and of ALT in 14%, of the patients. A total 
Table 1 Summary of published studies with T-DM1
Trial name Patients, n Treatment groups Results Reference
Phase 1
 TDM3569g
  Cohort 1 24 Dose escalation, T-DM1 q3 weeks ORR, 44%; CBR, 73% 17
  Cohort 2 28 Dose escalation, T-DM1 q1 week ORR, 46.4% 18
Phase 2
 TDM4258g 112 T-DM1: 3.6 mg/kg IV q3 weeks PFS, 4.6 months; ORR, 26% 20
 TDM4374g 110 T-DM1: 3.6 mg/kg IV q3 weeks PFS, 7.3 months; ORR, 35%; CBR, 48% 21
 TDM4450g 137 T-DM1: 3.6 mg/kg IV versus docetaxel + trastuzumab PFS, 14.2 months; ORR, 64% 22
 TDM4373g 64 T-DM1: 3.6 mg/kg IV + pertuzumab 840 mg loading  
dose followed by 420 mg IV q3 weeks
PFS, 6.6 months; ORR, 57% 23
Phase 3
 EMILIA 991 T-DM1: 3.6 mg/kg IV q3 weeks versus capecitabine +  
lapatinib
OS, 30.9 months; PFS, 9.6 months;  
ORR, 44%
24
 TH3RESA 602 T-DMI: 3 mg/kg IV q3 weeks versus physician choice PFS, 6.2 months; ORR, 31% 25
Abbreviations: T-DM1, trastuzumab emtansine; q1, weekly; q3; every 3 weeks; ORR, objective response rate; CBR, clinical benefit rate defined as objective response plus 
stable disease lasting at least 6 months; IV, intravenous; PFS, progression-free survival; OS, overall survival; EMILIA, An Open-label Study of Trastuzumab Emtansine (T-DM1) 
vs Capecitabine + Lapatinib in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer; TH3RESA, A Study of Trastuzumab Emtansine in Comparison 
With Treatment of Physician’s Choice in Patients With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy; HER2, 
human growth factor receptor 2.
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of nine patients (8%) experienced grade 3 or higher hepatic 
event, including seven patients with grade 3 laboratory 
abnormalities, one patient with grade 3 liver toxicity, and one 
patient who had a fatal hepatic event. Thrombocytopenia was 
also observed in 38% of patients. However, hemorrhagic 
events were typically mild, with the exception of one grade 3 
epistaxis. Similar to the TDM4258 study,22 no patients came 
off study because of cardiac toxicity.23
The first randomized study to evaluate T-DM1 was a 
phase 2 trial (TDM4450g) comparing q3 weekly T-DM1 to 
q3 weekly docetaxel plus trastuzumab in 137 patients with 
previously untreated HER2+ MBC.24 Patients in the control 
group received trastuzumab (8 mg/kg intravenous loading 
dose, followed by 6 mg/kg thereafter) plus docetaxel (75 or 
100 mg/m2, per investigator choice). The ORR (58% in the 
control group versus 64% in the T-DM1 group; P=0.458) 
and clinical benefit rate were similar in the two treatment 
groups; however, T-DM1 was associated with a significant 5 
month prolongation in median PFS (9.2 months versus 14.2 
months; hazard ratio [HR], 0.59; 95% confidence interval 
[CI], 0.36–0.97). The median duration of response was 9.5 
months in the docetaxel/trastuzumab group and was not 
reached in the TDM-1 group. Importantly, there was a much 
lower rate of grade 3/4 AEs in the T-DM1 group (90.9% ver-
sus 46.4%), underscoring the considerable safety imparted by 
targeted delivery of chemotherapy using an ADC that has a 
stable linker. In fact, grade 4 AEs occurred in 58% of patients 
in the standard docetaxel/trastuzumab group compared with 
only 6% in the T-DM1 group. In the docetaxel/trastuzumab 
group, the most common toxicities were alopecia, neutro-
penia, diarrhea, and fatigue. More patients in the control 
group used colony-stimulating factors compared with in the 
T-DM1 group (44% versus 6%). In the TDM-1 group, the AEs 
consisted mostly of fatigue, nausea, elevated serum aspartate 
aminotransferase, fever, and headache.24 The lower rate of 
AEs in the T-DM1 group translated to an improvement in 
quality of life. The time to a decrease in 5 or more points in the 
Trial Outcome Index-Physical/Functional/Breast (TOI-PFB) 
score was significantly delayed in the T-DM1 group (3.5 
months in the control group versus 7.5 months in the T-DM1 
group; HR, 0.58; 95% CI, 0.36–0.92; P=0.022).24
The safety and activity of dual-HER2 (see Table 1) 
targeted therapy with T-DM1 plus another HER2-targeted 
monoclonal antibody, pertuzumab, was evaluated in a phase 
2a trial, TDM4373g.25 In this study, 64 patients with HER2+ 
MBC (43 in the second-line or greater setting and 21 in the 
first-line setting) were treated with T-DM1 (3.6 mg/kg) plus 
pertuzumab (840 mg loading dose, followed by 420 mg) q3 
weeks. Of the 21 first-line patients, 86% had received tras-
tuzumab in the early-stage setting. The 43 patients who were 
previously treated for MBC had received a median of six prior 
lines of nonhormonal therapy. The ORR for the entire popu-
lation was 41%. In the first-line patients, the ORR was 57% 
and in the advanced setting was 33%. The median PFS was 
6.6 months, with 7.7 months in the first-line and 5.5 months 
in the second-line patients and beyond. The most common 
grade 3 or higher AEs were thrombocytopenia (13%), fatigue 
(11%), and transaminase elevations (9%).25
Phase 3 trials
In the landmark phase 3 EMILIA trial, 991 patients with 
metastatic or locally advanced trastuzumab-pretreated HER2+ 
disease were randomly assigned to receive either lapatinib 
(1,250 mg daily continuously) plus capecitabine (1,000 mg/m2 
by mouth twice a day, 14 days on, 7 days off) or T-DM1 q3 
weeks.26 The primary endpoints were PFS, OS, and safety. The 
median PFS was 9.6 months in the T-DM1 group versus 6.4 
months in the lapatinib plus capecitabine group (HR, 0.65; 
95% CI, 0.55–0.77; P,0.001). At the second interim analysis, 
median OS crossed the stopping boundary for efficacy and 
was increased by 5 months in the T-DM1 group (30.9 months 
versus 25.1 months; HR, 0.68; 95% CI, 0.55–0.85; P,0.001). 
Secondary endpoints including ORR (43.6% versus 30.8%; 
P,0.001) and median duration of response (12.6 months ver-
sus 6.5 months) favored T-DM1. In addition, the median time 
to decrease of 5 points or more in the Functional Assessment 
of Cancer Therapy-Breast (FACT-B TOI) score was delayed 
in the T-DM1-treated patients (7.1 months versus 4.6 months; 
HR, 0.80; 95% CI, 0.67–0.95; P=0.012).
Grade 3/4 AEs were less frequent in the T-DM1-treated 
patients compared with the control group patients (40.8% 
versus 57.0%). The most common grade 3/4 AEs in the 
T-DM1-treated patients were thrombocytopenia and increased 
liver transaminases, and the most common grade 3/4 AEs 
in control group patients were diarrhea and palmar-plantar 
erythrodysesthesia. Of note, the rate of cardiac dysfunction 
was similar in both groups, with a total of 1.7% of patients 
in the T-DM1 group and 1.6% of patients in lapatinib plus 
capecitabine group having an ejection fraction that was below 
50%, or at least 15% below baseline. Grade 3 congestive heart 
failure was seen in only one patient in the T-DM1 group.26
The activity of T-DM1 in the lapatinib-pretreated HER2+ 
MBC setting was explored in the TH3RESA study.27 In this 
second phase 3 trial of T-DM1, patients who had received 
at least two HER2-targeted therapies for advanced disease, 
including both trastuzumab and lapatinib, were randomized 
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in an open-label fashion to receive T-DM1 or treatment of 
physicians choice (TPC). A total of 602 patients were ran-
domized in a 2:1 ratio to T-DM1 (3.6 mg/kg q21 days) or TPC. 
Stratification was based on region of the world, number of 
prior regimens, and presence or absence of visceral disease. 
Coprimary endpoints were investigator-assessed PFS and 
OS in the intent-to-treat population. Patients had received a 
median of four prior regimens for MBC. In the TPC group, 
83% of the patients received HER2-targeted therapy as part of 
their regimen, and 17% received single-agent chemotherapy 
alone. The median PFS was significantly longer in the T-DM1 
group compared with in the TPC group (6.2 months versus 
3.3 months; HR, 0.528; 95% CI, 0.442–0.661; P,0.0001). 
There was a trend for improved survival with T-DM1, but 
the stopping boundary was not crossed at the first interim 
analysis. The ORR was also significantly improved in patients 
with measurable disease treated with T-DM1 (31% versus 9%, 
95% CI, 16.2–29.2; P,0.0001). In terms of grade 3 or greater 
toxicities, thrombocytopenia was the only AE reported more 
commonly in the T-DM1 group. Overall, 18% of patients 
in the T-DM1 group and 21% of patients in the TPC group 
experienced a significant adverse event.27
The consistent PFS and ORR benefit seen in these two 
published phase 3 trials confirm that T-DM1 is a highly active 
and better-tolerated agent for patients with HER2+ MBC 
after the first-line setting (Table 1). Unfortunately, patients 
eventually experience disease progression on T-DM1; hence, 
discovering molecular markers that can predict response or 
resistance to this therapy remains a high priority.
Predictors of response  
or resistance to T-DM1
HER2 expression levels
HER2 expression levels do appear to influence the efficacy 
outcomes associated with T-DM1. In exploratory analyses of 
several phase 2 and phase 4 studies, HER2 expression levels 
were measured on archived tumor samples by quantitative 
reverse transcription polymerase chain reaction. Patients were 
grouped according to whether their HER2 expression was 
greater than or less than the median. Of 50 patients included 
in the TDM4258g analysis, the median PFS was not reached 
(95% CI, 4.6 months– non estimable [NE]) for those with 
median HER2 expression or worse and was 4.2 months (95% 
CI, 2.7–6.8 months) for those patients with lower than median 
HER2 expression.22 In the TDM4374 trial, patients in whom 
HER2 expression was at least the median had a higher ORR of 
42% and a PFS of 8.0 months compared with those in whom 
HER2 expression level was below the median (ORR, 38%; 
PFS, 6.2 months).23 Improved ORR and PFS were also reported 
in pertuzumab plus T-DM1-treated patients with tumor HER2 
mRNA levels at the median or higher in the TDM4373g study.25 
A similar analysis was undertaken in the TDM4450 study, in 
which HER2 mRNA levels were available for 116/137 patients: 
61 in the control group and 55 in the T-DM1 group.28 In this 
randomized study, the relative risk of progressive disease 
in the overall population was reduced by 41% with T-DM1 
compared with chemotherapy plus trastuzumab. This effect 
was even higher in patients with HER2 mRNA levels at least 
the median (61% relative risk reduction favoring the T-DM1 
group; HR, 0.39; 95% CI, 0.18–0.85) compared with those 
with HER2 mRNA levels less than the median (15% relative 
risk reduction favoring the T-DM1 group; HR, 0.85; 95% CI, 
0.44–1.67). The median PFS was not reached in the T-DM1 
group in patients with HER2 mRNA at least median and was 
10.6 months for those with HER2 mRNA less than median. 
In the control group  (trastuzumab/docetaxel), median PFS 
was not significantly different (8.8 months versus 9.8 months 
with HER2 mRNA at the median or higher versus lower than 
median, respectively).28 Biomarker analysis of the EMILIA 
trial further confirmed this observation. Patients with tumors 
expressing HER2 levels greater than median had an OS of 34.1 
months and a PFS of 10.6 months compared with 26.5 months 
and 8.2 months, respectively, for patients with HER2 levels less 
than or equal to the median.29 The consistent observation that 
HER2 expression influences response to T-DM1 is intriguing, 
but further analyses including prospective studies are needed 
to confirm the threshold of HER2 expression required for a 
response to this therapy.
Drug efflux pumps
P glycoprotein I (also known as MDR1) is the best-known 
transporter that mediates the efflux of toxins and drugs from 
the cell. MDR1 expression has been associated with poor 
response to chemotherapy in malignancies.30 In one study, 
a T-DM1-resistant cell line was shown to have upregulation of 
the MDR transporters.31 Another study evaluated two cell lines 
(JIMT1 and MDA-MB-361) that had conditioned resistance 
to a trastuzumab–maytanisinoid conjugate (JIMT-TM and 
361-TM) and showed that JIMT-TM resistance may be related 
to downregulation in HER2 expression, as well as increased 
expression in proteins related to posttranslational modification 
and endosomal proteins; however, drug efflux proteins were 
not altered. In contrast, in 361-TM cells, an increase in ABCC 
(MRP1) was seen without any changes in ABCB1 (MDR1).32 
Additional studies are needed to assess the importance of MDR 
in mitigating clinical resistance to T-DM1.
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PiK3CA mutations
At least one mechanism involved in the oncogenic func-
tion of HER2 is activation of the phosphoinositide 
3-kinase (PI3K)–Akt signaling pathway. Activating mutations 
in the catalytic subunit of the PI3K (PIK3CA) can result in 
increased activity of this pathway.33 It is estimated that 20%–40% 
of HER2+ breast cancers have activating mutations in PIK3CA.34 
Preclinical work has demonstrated that HER2+/PIK3CA mutant 
tumors are resistant to trastuzumab alone or in combination with 
lapatinib or pertuzumab.35  Exploratory analyses from two recent 
trials confirm this laboratory phenomenon. The NeoSphere 
study was a randomized phase 2 trial that demonstrated that dual 
HER2-targeting with neoadjuvant pertuzumab, trastuzumab, and 
docetaxel was associated with a higher pathological complete 
response (pCR) rate of 45.8% compared with three other com-
binations (docetaxel and trastuzumab [pCR, 29%], trastuzumab 
and pertuzumab [pCR, 16.8%], and docetaxel and pertuzumab 
[pCR, 24.0%]). The rate of pCR was lower in all four group in 
patients whose tumors bore PIK3CA mutations (24%) compared 
with patients without PIK3CA mutations (35%).36 Biomarker 
analysis of the NeoALTTO trial, another neoadjuvant study in 
HER2+ breast cancer that evaluated lapatinib and/or trastuzumab 
plus paclitaxel, also confirms this observation.37 Patients whose 
tumors had PIK3CA mutations had a lower pCR rate, with the 
most notable difference in the group containing both lapatinib 
and the trastuzumab group (55.8% without mutations versus 
28.6% with mutations).38 Interestingly, an exploratory analysis 
on the EMILIA trial confirms that PIK3CA mutations were 
associated with a decrease in PFS in the capecitabine/lapatinib 
group (6.4 months wild-type versus 4.3 months mutated); 
however, the presence of PIK3CA mutations did not correlate 
with outcome in the T-DM1 group (9.8 months wild-type 
versus 10.9 months mutated).29 Thus, although the presence of 
PIK3CA mutations may be prognostic for poorer outcome in 
patients treated with trastuzumab, pertuzumab, or lapatinib, this 
marker does not appear to be prognostic of outcome in patients 
treated with T-DM1.
Neuregulin-HER3 signaling
Recent translational work provides some evidence that 
resistance to T-DM1 may in part be mediated by neuregulin 
and HER3 signaling. Neuregulin-1 is a ligand that binds to 
HER3, inducing a conformational change allowing HER3 to 
dimerize with HER2. HER2:HER3 dimers are highly potent 
activators of the PI3K pathway.39 Pertuzumab, a monoclonal 
HER2-targeted antibody, binds to and blocks HER2 at the 
HER3-binding domain, thus abrogating PI3K signaling. 
Preclinical work led by Phillips and colleagues demonstrated 
that in the presence of neuregulin, enhanced antiproliferative 
effects were seen when T-DM1 was combined with pertu-
zumab compared with T-DM1 alone in three cell lines (Calu-3 
lung, BT-474, and SK-BR-3). There was no combination 
effect seen in KPL-4 cells that harbor PIK3CA-activating 
mutations, however, even in the presence of neuregulin.40 
These intriguing preclinical results led to the phase 1b/2 
TDM4373g clinical trial evaluating pertuzumab plus T-DM1 
in HER2+ MBC (see “Phase 2 trials” section).25
Future directions
Although the benefit of T-DM1 in patients with pretreated, 
locally advanced, or metastatic HER2+ breast cancer is 
clear, additional studies are needed to evaluate the ben-
efit of T-DM1 in combination with other agents as well as 
its role in early-stage HER2+ disease. One ongoing trial, 
MARIANNE (A Study of Trastuzumab Emtansine [T-DM1] 
Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab 
[Herceptin] Plus a Taxane in Patients With Metastatic Breast 
Cancer; NCT01120184), is a three-group study in previ-
ously untreated locally advanced or metastatic HER2+ breast 
cancer that compares trastuzumab plus taxane, T-DM1 plus 
pertuzumab, and T-DM1 plus placebo. All patients are treated 
until disease progression with primary endpoint of PFS and a 
secondary endpoint of OS, as well as biomarker studies. This 
study has completed accrual with results anticipated in late 
2014. The TDM4652g trial (NCT00951665) is a phase 1b trial 
exploring the combination of T-DM1, paclitaxel ± pertuzumab 
in previously treated patients with metastatic breast cancer. 
Finally, the BP22572 trial (NCT00934856) is a phase 1b/2a 
trial to explore combination of T-DM1 with docetaxel with or 
without pertuzumab in previously treated HER2+ MBC.
The activity and safety of T-DM1 in early breast cancer is 
being explored by several other trials. The ATEMPT (T-DM1 vs 
Paclitaxel/Trastuzumab for Breast, NCT01853748) trial is a 
phase 2 study in which patients with stage 1 HER2+ breast 
cancer are randomized to T-DM1 every 3 weeks for 17 weeks 
or to a combination of trastuzumab and paclitaxel weekly 
for 12 weeks followed by maintenance trastuzumab to com-
plete 1 year. The primary endpoint of the trial is disease-free 
survival, and the secondary endpoint is OS. The random-
ized, open-label phase 3 KAITLIN (A Study of Kadcyla 
[Trastuzumab Emtansine] Plus Perjeta  [Pertuzumab] Following 
 Anthracyclines in Comparison With  Herceptin [Trastuzumab] 
Plus Perjeta and a Taxane Following Anthracyclines as 
Adjuvant Therapy in Patients With  Operable HER2-Positive 
Primary Breast Cancer, NCT01966471) trial is compar-
ing the combination of trastuzumab and pertuzumab plus 
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a taxane versus T-DM1 plus pertuzumab after completion 
of adjuvant anthracycline- containing chemotherapy. The 
role of T-DM1 in the neoadjuvant setting is being explored 
in the KRISTINE (A Study Comparing Kadcyla Plus Perjeta 
Treatment to Chemotherapy Combined With Herceptin 
Plus Perjeta in Patients With HER2-Positive Breast Cancer, 
NCT02131064) trial. In this open-label phase 2 trial, patients 
are randomized to either six cycles of q3 weekly docetaxel, 
carboplatin, trastuzumab, and pertuzumab or T-DM1 and pertu-
zumab before definitive surgery. Another neoadjuvant study is 
ADAPT (A Prospective, Randomized Multicenter, Open-label 
Comparison of Preoperative Trastuzumab Emtansine [T-DM1] 
With or Without Standard Endocrine Therapy vs Trastuzumab 
With Standard Endocrine Therapy Given for Twelve Weeks in 
Table 2 Ongoing clinical trials with T-DM1
Trial name Phase Patient population Number to 
be enrolled
Treatment groups
MARIANNE (NCT01120184) 3 First-line HER2+ MBC 1,092 T-DM1 + placebo versus T-DM1 + pertuzumab versus 
trastuzumab + a taxane
TDM4652g (NCT00951665) 1b Previously treated HER2+ MBC 107 T-DM1 + paclitaxel ± pertuzumab
BP22572 (NCT00934856) 1b/2a Previously treated 
HER2+ MBC
99 T-DM1 + docetaxel ± pertuzumab
KAITLIN (NCT01966471) 3 Adjuvant 2,500 AC/FEC T-DM1/pertuzumab versus  
AC/FEC  trastuzumab/pertuzumab/taxane
ATEMPT (NCT01853748) 2 Stage 1 adjuvant 500 T-DM1 ×1 year versus paclitaxel/trastuzumab × 12 weeks, 
followed by trastuzumab maintenance to complete 1 year
KRISTINE (NCT02131064) 2 Neoadjuvant 432 T-DM1/pertuzumab versus taxotere/carboplatin/
trastuzumab/pertuzumab
ADAPT (NCT01745965) 2 Neoadjuvant 380 T-DM1 ± endocrine therapy versus trastuzumab + 
endocrine therapy for 12 weeks before surgery
KATHERINE (NCT01772472) 3 Residual disease after  
neoadjuvant therapy
1,484 T-DM1 versus trastuzumab maintenance for 14 cycles 
after surgery
Trastuzumab and Pertuzumab 
followed by T-DM1 in MBC  
(NCT01835236)
2 First-line HER2+ MBC 208 Trastuzumab and pertuzumab (no chemotherapy) in 
first-line MBC followed by T-DM1 in second-line MBC in 
the event of progression versus trastuzumab/pertuzumab/
paclitaxel or vinorelbine in first-line MBC followed by 
T-DM1 in second-line MBC in event of progression
BYL719 + T-DM1 in HER2(+) 
Metastatic Breast Cancer  
Pts who Progress on Prior  
Trastuzumab and Taxane Tx  
(NCT02038010)
1 Previously treated HER2+  
MBC with progression on prior 
trastuzumab and taxane-based  
therapy
28 BYL719 (PI3K inhibitor) orally daily on days 1–21 and 
T-DM1 every 3 weeks
GDC-0941 administered orally 
to patients with Trastuzumab-
DM1 or trastuzumab 
(NCT00928330)
1 Previously treated HER2+  
MBC who progressed on  
trastuzumab-based therapy
57 Oral GDC-0941 (PI3K inhibitor) daily and T-DM1 or 
trastuzumab
STELA (NCT02073916) 1 Previously treated MBC with  
at least two prior therapies
18 T-DM1 intravenously every 3 weeks in combination with 
lapatinib daily plus abraxane intravenously weekly
ONT380 + TDM1 
(NCT01983501)
1 Previously treated HER2+ MBC 
with taxane and trastuzumab
48 ONT380 orally twice a day with T-DM1 intravenously
Phase 1b Study of  
PD-0332991 in Combination  
With T-DM1 (NCT01976169)
1 Previously treated MBC with  
HER2+ and RB proficient tumor
17 T-DM1 intravenously on day 1 with PD-0332991 
(palbociclib) on days 5–18 of every 21-day cycle
Abbreviations: MARIANNE, A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients 
With Metastatic Breast Cancer; HER, human growth factor receptor; MBC, metastatic breast cancer; TDM4652g, A Study of Trastuzumab Emtansine, Paclitaxel, and 
Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer; T-DM1, trastuzumab emtansine; BP22572, A Study of Trastuzumab Emtansine 
(T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Patients With Advanced Breast Cancer; KAITLIN, A Study of Kadcyla (Trastuzumab Emtansine) 
Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy 
in Patients With Operable HER2-Positive Primary Breast Cancer; AC/FEC, adriamycin, cyclophosphamide/5-fluorouracil, epirubicin, and cyclophosphamide; ATEMPT, T-DM1 
vs Paclitaxel/Trastuzumab for Breast; KRISTINE, A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients 
With HER2-Positive Breast Cancer; ADAPT, A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or 
Without Standard Endocrine Therapy vs Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer 
Within the ADAPT Protocol; KATHERINE, A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer 
Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy; GDC-0941 administered orally to patients with Trastuzumab-DM1 or 
trastuzumab, Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast 
Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy; STELA, TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer; ONT380 + 
TDM1, A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer.
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Patients With Operable HER2+/HR+ Breast Cancer Within 
the ADAPT Protocol, NCT01745965), a randomized trial 
evaluating T-DM1 (with or without endocrine therapy) ver-
sus trastuzumab plus endocrine therapy for 12 weeks before 
definitive surgery in HER2+/hormone receptor–positive breast 
cancer. The KATHERINE (A Study of Trastuzumab Emtansine 
Versus Trastuzumab as Adjuvant Therapy in Patients With 
HER2-Positive Breast Cancer Who Have Residual Tumor in 
the Breast or Axillary Lymph Nodes Following Preoperative 
Therapy, NCT01772472) trial will enroll patients who had 
residual disease at the time of definitive surgery after stan-
dard neoadjuvant trastuzumab-based therapy to either T-DM1 
or trastuzumab maintenance for 14 cycles after surgery.
In addition to the abovementioned trials, studies are ongo-
ing that will evaluate the combination of T-DM1 with other 
biologically targeted therapies. The BYL719 + T-DM1 trial 
(BYL719 + T-DM1 in HER2[+] Metastatic Breast Cancer 
Pts Who Progress on Prior Trastuzumab and Taxane Tx, 
NCT02038010) is a phase 1 trial exploring the safety of combina-
tion of BYL719, a PI3K inhibitor with T-DM1 in patients whose 
metastatic disease has progressed on prior trastuzumab and 
taxane-based therapy. Another PI3K inhibitor, GDC-0941 is also 
being evaluated in a phase 1 study (GDC-0941 + TDM1 or Tras-
tuzumab, Trastuzumab and Trastuzumab-MCC-DM1 Admin-
istered Intravenously and GDC-0941  Administered Orally to 
Patients With HER2-Positive Metastatic Breast Cancer Who 
Have Progressed on Previous Trastuzumab-Based Therapy, 
NCT00928330) in combination with trastuzumab or T-DM1 
for patients whose disease progressed on previous trastuzumab-
based therapy. The STELA (TDM1 With Abraxane and Lapatinib 
for Metastatic HER2 Positive Breast Cancer, NCT02073916) 
trial is an open-label study to assess the tolerability and safety of 
combination of T-DM1 to lapatinib and nab-paclitaxel in patients 
with HER2+ breast cancer who have received at least two prior 
therapies for their malignant disease. Dual HER2 blockade 
with the novel small molecule inhibitor of HER2, ONT-380 (A 
Phase 1b Study of ONT-380 Combined With Ado-trastuzumab 
Emtansine [T-DM1] in Patients With HER2+ Breast Cancer), 
along with T-DM1 is being evaluated in a small phase 1 study 
(NCT01983501) that will enroll 48 patients. Finally, the potential 
benefit of CDK4/6 inhibition in combination with T-DM1 will be 
evaluated in a phase 1 study of PD-0332991 along with T-DM1 
(NCT01976169). In this study patients, will receive T-DM1 on 
day 1 followed by PD-0332991 orally on days 5–18 of every 
21-day cycle. The ongoing clinical trials have been summarized 
in Table 2.  Collectively, these trials will help not only address the 
role T-DM1 may have in early breast cancer but also elucidate 
the benefit of T-DM1 in combination with chemotherapy as well 
as other targeted therapies such as pertuzumab.
Conclusion
T-DM1 is the first example of a successfully developed ADC 
for the treatment of breast cancer. The collective published 
studies in phase 1 and 2, as well as the results of two large 
randomized phase 3 trials, EMILIA and TH3RESA, have 
demonstrated that T-DM1 is an efficacious and safe thera-
peutic intervention for HER2+ metastatic breast cancer. In 
spite of its success, disease progression on T-DM1 does occur; 
therefore, greater understanding of pathways of resistance 
is crucial in improving the efficacy. Ongoing studies will 
evaluate combining T-DM1 with other targeted therapies and 
using T-DM1 in the early setting.
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